In a subsequent phase 3 trial (MAGRIT) [21], 2227 MAGE-A3 positive patients with completely-resected stage IB, II, and IIIA NSCLC were randomised, in a 2:1 ratio, to receive the MAGE-A3 vaccine or placebo. This evidence concerns the gene MAGEA3 and non-small cell lung carcinoma.